Sign in

    Azenta Inc (AZTA)

    Q2 2024 Earnings Summary

    Reported on Feb 20, 2025 (After Market Close)
    Pre-Earnings Price$54.07Last close (May 8, 2024)
    Post-Earnings Price$51.15Open (May 9, 2024)
    Price Change
    $-2.92(-5.40%)

    What went well

    • Strong growth in the Sample Management Solutions (SMS) and Multiomics segments, with large stores growing 50% this quarter and Multiomics growing when everybody else is down, indicating robust demand and effective strategies in these key areas.
    • Significant double-digit increases in bookings for the Consumables & Instruments business, with Q2 bookings the highest since the pandemic, suggesting a rebound in demand and potential future revenue growth.
    • Consistent double-digit growth in China over the past four quarters, outperforming the market, driven by strong local presence and capabilities, leading to increased market share and strengthening global operations.

    What went wrong

    • Lowered revenue guidance due to challenges in the B Medical segment: The company adjusted down its full-year revenue outlook for the B Medical segment, citing unpredictable conversion of its robust pipeline into revenue. This adjustment brings the company's full-year organic revenue guide to a range of negative 1% to positive 1%, reflecting potential stagnation in growth.
    • Continued headwinds in the Consumables & Instruments business with uncertain recovery timing: The Consumables & Instruments segment remains challenged due to capital spending constraints and longer purchasing cycles. While the pipeline is strong, the timing of orders remains uncertain, and recovery is dependent on biotech funding, which may lag.
    • Operational delays impacting revenue recognition: Supply chain delays in the Sample Management Solutions segment are causing orders to be pushed from Q3 into Q4. This indicates operational challenges that may affect quarterly results and revenue predictability.

    Q&A Summary

    1. B Medical Guidance Reduction
      Q: Why is B Medical guidance being lowered?
      A: B Medical's guidance is lowered due to uncertainty in the $60 million DRC contract timing and the exit from the U.S. non-vaccine cold chain (non-VCC) market. These factors are key contributors to the reduction.

    2. EPS Guidance Increase Despite Lower Revenue
      Q: How is EPS guidance raised despite lowered revenues?
      A: The EPS guidance increased by $0.08 due to expected $20 million revenue step-up from Q3 to Q4 and progress on cost reduction initiatives like site exits and organizational simplification. Gross profit improvements and the Ascend 2026 program contribute to confidence in meeting EBITDA and EPS targets.

    3. Sample Management Revenue Timing
      Q: Is Sample Management growth expected to accelerate in Q4?
      A: Yes, a $2 million order in Sample Management was pushed from Q3 to Q4 due to minor supply chain delays. This will result in a revenue step-up from Q3 to Q4, with low single-digit growth in Q3 and higher growth in Q4.

    4. Large Stores Revenue Growth
      Q: How is the large stores business performing?
      A: Large stores revenue grew 50% year-over-year in the quarter, and the backlog continues to grow even as revenue increases. There's high interest in large automated stores, and the BioArc Ultra launch is contributing positively.

    5. NGS Transition Impact
      Q: What's the status of the NGS transition and its impact?
      A: The shift to NovaSeq X Plus is ongoing, causing a short-term dip as volumes ramp up. Despite this, gross margins are holding or improving, and the company is ahead of prior transitions.

    6. Multiomics Growth in China
      Q: What's driving Multiomics growth in China?
      A: Multiomics in China has seen double-digit growth for four consecutive quarters despite market downturns. Success is due to strong local presence, aggressive sales teams, and increased capacity, including a new facility in Suzhou.

    7. CEO Retirement and Succession
      Q: What is the plan for CEO succession after Steve's retirement?
      A: The Board seeks someone to maintain the current strategy and leverage market opportunities. Steve will support the transition and is confident in the company's future leadership.

    8. Instruments and Consumables Outlook
      Q: Are there signs of improvement in Instruments and Consumables?
      A: Consumables bookings were very strong, with significant double-digit sequential and year-over-year increases, reaching the highest levels since the pandemic. Instruments bookings were soft due to capital spending constraints, but the pipeline is strong and demand is healthy.

    9. Impact on Future Guidance
      Q: Does lower 2024 revenue guidance affect 2025 and 2026 outlook?
      A: No, the lower 2024 revenue guidance does not change the 2025 and 2026 guidance. The company feels confident about the trajectories of Sample Management and Multiomics, expecting continued growth.

    10. Forecasting B Medical Revenue
      Q: Can B Medical revenue be better forecasted long-term?
      A: Forecasting B Medical over longer periods remains challenging. About half of the revenue comes from funding agencies, providing some visibility, but timing of orders is hard to predict. The vaccine cold chain portion is expected to be around $100 million annually with low single-digit growth.

    Related Publications